Gujarat Inject Quarterly Results for Trading Insights
In 2026, Gujarat Inject (GUJINJEC) reported revenue ₹12 Cr and net profit ₹1 Cr. For annual financials, live price and key ratios, visit Gujarat Inject share price chart.
GUJINJEC Quarterly Results — Revenue, Profit & EPS Highlights
Gujarat Inject latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with GUJINJEC stock valuation models to assess whether the stock is under or overvalued.
- Revenue of ₹19 Cr in March 2025 (+0.0% vs March 2025, +216.7% vs March 2024)
- Net Profit of ₹1 Cr in March 2025 (+0.0% vs March 2025)
- EBITDA of ₹1 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 6.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹0.70 in March 2025 (+0.0% vs March 2025)
Gujarat Inject Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUJINJEC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 12 | 19 | 6 | 1 | 0 | -36.8% | - |
| Net Profit (₹ Cr) | 1 | 1 | 0 | 0 | 0 | - | - |
| EBITDA (₹ Cr) | 1 | 1 | 0 | 0 | 0 | - | - |
| EPS (₹) | 0.30 | 0.70 | 0.09 | 0.05 | 0.00 | - | - |
| Operating Margin (%) | 4.0% | 6.0% | 1.0% | -217.0% | -200.0% | - | - |
GUJINJEC Share Price Trend — 1-Year Movement Across Quarterly Results
Gujarat Inject 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Gujarat Inject share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUJINJEC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gujarat Inject latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1878.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6760.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.3 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹149,048.00 Cr | 4405.7 | 3,219 | 591 | +11.3% | - | 18.4% | 251.2 |
|
Cipla
Mar 2026 |
₹116,053.85 Cr | 1432.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 208.5 |
|
Dr Reddys Laborator…
Mar 2026 |
₹108,804.06 Cr | 1336.7 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 504.4 |
All amounts in ₹ Crores